Savara Inc.
Records under this name other than patents Savara Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,757,411 | Poloxamer therapy for heart failure Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,403,941 | Poloxamer Composition Free of Long Circulating Material and Methods for Production and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,501,577 | Poloxamer Composition Free of Long Circulating Material and Methods for Production and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,155,679 | Poloxamer Composition Free of Long Circulating Material and Methods for Production and Uses Thereof Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,572,774 | Dry Powder Vancomycin Compositions and Associated Methods Lapsed on the fee record Ended Feb 21, 2025 · Low confidence | Lapsed on the fee record | Ended Feb 21, 2025 | Low confidence |
| US 9,526,695 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,696 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,697 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,698 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,486,462 | Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Lapsed on the fee record Ended Nov 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2024 | From the USPTO record |